Navigation Links
Led by New Patents to Identify Malicious Intent on Mobile Devices, BioCatch Significantly Expands its IP Portfolio
Date:12/7/2016

TEL AVIV, Israel, December 7, 2016 /PRNewswire/ --

BioCatch, the global leader in behavioral biometrics, reported a banner year with the expansion of its patent portfolio, which grew to over 40 granted and pending patents.

The Company's IP portfolio expansion was led by its recently filed patent entitled "System, Device, and Method Estimating Force Applied to a Touch Surface," which covers technology that enables device makers to forego costly hardware components needed to estimate the force and pressure applied to touch surfaces on devices, such as smartphones and smartwatches.

Measuring the pressure from touching a screen is an important capability for device makers to enhance usability, and for application developers who could leverage this information to increase security and enable continuous authentication based on interaction with a screen. BioCatch has invented a unique method for collecting data that allows device makers to gather information from a device, and show high resolution results of finger touch areas over time without needing additional hardware.

"BioCatch's 'touch-force' patent, along with our entire IP portfolio, are the result of the almost obsessive focus we place on innovation to counter the increasing sophistication of cyberattacks," said Eyal Goldwerger, CEO of BioCatch. "The emphasis on mobile reflects how important the platform is to our target customers who need to prevent fraud while maintaining an optimum user experience."

In addition to the touch-force patent, BioCatch obtained 8 new patents this year, including:

-   Multiple User Detection: Patent US 9477826 extends the Company's ability to detect a user's identity by using specific parameters that can recognize multiple people using shared credentials. The application of this patent goes beyond traditional fraud prevention in banking, addressing the needs of the software and content monetization market (IP protection, licensing, usage tracking, etc.)

-   Device Spoofing Circumvention: Patent US 9483292 describes a way to detect whether the device ID has been masked, differentiating between a genuine user who utilizes a real-world computing device in order to access a service or a remote server and an attacker who accesses the service or remote server by utilizing a Virtual Machine. The application of this patent speaks to fraudsters' ability to hide device ID information, circumventing a widely used fraud prevention methodology.

BioCatch has also filed and won patents relating to malware, robotic detection and identification of remote access Trojans (RATs). This class of patents is designed to prevent next-generation malicious automatic attacks by using invisible challenges to create subconscious responses by users, allowing BioCatch to generate and analyze those behavioral responses. The monitored interactions are used to detect attackers who utilize remote access channels, malicious code injections and automatic scripts.

"The market is recognizing that traditional fraud prevention measures like device authentication, IP recognition and geolocation are being circumvented and new ways of understanding how cybercriminals behave must be examined," said Avi Turgeman, CTO and co-founder of BioCatch. "BioCatch continues to focus on the authentication of user behavior, while looking for new data that we learn from. Our patents result in new capabilities that can outpace and outsmart cybercriminals, regardless of the methodologies they use to commit their crimes."

About BioCatch 

BioCatch is a cybersecurity company that delivers behavioral biometrics analyzing human-device interactions to protect users and data. Banks and other enterprises use BioCatch to significantly reduce online fraud and protect against a variety of cyber threats, without compromising the user experience. For more information, please visit http://www.biocatch.com.

Media Contact:
Rachel Glaser
GK PR for BioCatch
rachel@gkpr.com
+972-54-250-9439

Frances Zelazny
Vice President of Marketing, BioCatch
frances.zelazny@biocatch.com
+1-917-862-1373


'/>"/>
SOURCE BioCatch
Copyright©2016 PR Newswire.
All rights reserved


Related biology news :

1. NXT-ID Patents Electronic Crypto-Currency Management Technology
2. NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology
3. NXT-ID Patents Behavior-Directed Payments
4. NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe
5. NXT-ID Patents Voice Directed Payments
6. NXT-ID Patents Collaborative Services to Enable the "Internet of Things"
7. NXT-ID Patents Offline Local Identity Validation and Fraud Prevention System
8. PTS, Inc. Announces Two New Patents
9. Japan, China and South Korea account for 84 percent of the macroalgae patents
10. Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
11. Identifying the source of stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... ... urology practice in the Southeast, and its acclaimed pediatric urologists are among ... Hospitals rankings. This annual recognition signifies excellence among the country’s pediatric healthcare ...
(Date:7/17/2019)... ... July 16, 2019 , ... At nearly eleven years old, ... According to his owner, in the last year or so, he was a ... His veterinarian, Dr. Cindy Echevarria of VCA University Animal Hospital in Dallas, ...
(Date:7/11/2019)... ... July 11, 2019 , ... Spartan ... a partnership with LiquiTech, a leader in Legionella prevention for the health ... integrate Spartan’s innovative environmental DNA testing platform to provide a new approach ...
Breaking Biology News(10 mins):
(Date:7/11/2019)... ... 2019 , ... At the most recent stem cell training course ... under the R3 Heroes Program. The Veterans included individuals and families from all over ... to nominate a military Veteran, teacher or first responder to receive a regenerative therapy ...
(Date:7/9/2019)... (PRWEB) , ... July 08, 2019 , ... ... winner. The company’s SmartLight Indicator was recognized as the 2019 Innovative Product of ... industry forward. The prestigious awards were during Sensors Expo & Conference 2019, ...
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial impact ... to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... Over 142% increase in particle size , Over 3% alteration ...
(Date:6/18/2019)... (PRWEB) , ... June 18, 2019 , ... Personalized ... Investigational New Drug (IND) application to the FDA for use of a person’s own ... as a treatment of osteoarthritis in the knee. This IND is the first ...
Breaking Biology Technology: